{"nctId":"NCT02949362","briefTitle":"Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study","startDateStruct":{"date":"2016-12-09","type":"ACTUAL"},"conditions":["Short Bowel Syndrome"],"count":29,"armGroups":[{"label":"Standard of Care (SOC) Treatment +/- Teduglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Teduglutide","Other: SOC"]}],"interventions":[{"name":"Teduglutide","otherNames":[]},{"name":"SOC","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, subject informed assent) to participate in the study before completing any study-related procedures.\n2. Subject completed the TED-C13-003 study (including subjects in the standard of care treatment arm).\n3. Subject understands and is willing and able to fully adhere to study requirements as defined in this protocol.\n\nExclusion Criteria:\n\nThere are no exclusion criteria for this study.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs) in Retrospective Observation Period","description":"An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, was an important medical event. Number of participants with AEs, related AEs, serious adverse events (SAEs) and related SAEs of retrospective observation period were reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Height for Age Z-score up to Week 168 of Retrospective Observation Period","description":"Height was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age greater than or equal to \\[\\>=\\] 2 years old) and World Health Organization (age less than \\[\\<\\] 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Week 168 of retrospective observation period was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.128","spread":"0.0505"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Body Weight for Age Z-score up to Week 168 of Retrospective Observation Period","description":"Body weight was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \\>= 2 years old) and World Health Organization (age \\< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score up to Week 168 was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.181","spread":"0.0601"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Body Mass Index (BMI) for Age Z-score up to Week 168 of Retrospective Observation Period","description":"BMI Z-score was calculated by using the retrospective height and weight data. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \\>= 2 years old) and World Health Organization (age \\< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Week 168 of retrospective observation period was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.283","spread":"0.0646"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Prospective Study Period","description":"TEAEs are defined as AEs that started or worsened on or after the first dose of teduglutide treatment in the core study. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, was an important medical event. AESI was an TEAE or TESAE of scientific and medical concern specific to the sponsor's product or program and for which ongoing monitoring and immediate notification by the investigator to the sponsor. Number of participants With TEAEs, treatment -emergent serious adverse events (TESAEs) and adverse events of special interest (AESI) of Prospective study period were reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Height for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Height was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \\>= 2 years old) and World Health Organization (age \\< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Cycle 6 Week 12 during the end of teduglutide treatment period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"1.068"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Body Weight for Age Z-score up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Body weight was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \\>= 2 years old) and World Health Organization (age \\< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score up to Cycle 6 Week 24 during the end of teduglutide treatment period of prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"NA"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in BMI for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period","description":"BMI Z-score was calculated by using the height and weight data. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \\>= 2 years old) and World Health Organization (age \\< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for age Z-score up to Cycle 6 Week 12 during the end of teduglutide treatment period of prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"0.349"}]}]}]},{"type":"PRIMARY","title":"Average Total 48-Hour Urine Output up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Average total urine output was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average total 48-Hour urine output up to Cycle 6 Week 12 during the end of teduglutide treatment period of prospective study period was reported. Here, mL/kg/day is abbreviated as milliliter per kilogram per day.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.38","spread":"12.712"}]}]}]},{"type":"PRIMARY","title":"Average Total 48-Hour Urine Output up to Week 108 During the End of Non-Teduglutide Treatment (NTT) Period of Prospective Study Period","description":"Average total urine output was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average total 48-Hour urine output up to Week 108 during the end of NTT period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.86","spread":"9.956"}]}]}]},{"type":"PRIMARY","title":"Average Number of Stools Per Day up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Average number of stools per day was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average number of stools per day up to cycle 6 week 24 during the end of teduglutide treatment period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.50","spread":"NA"}]}]}]},{"type":"PRIMARY","title":"Average Number of Stools Per Day up to Week 120 During the End of NTT Period of Prospective Study Period","description":"Average number of stools per day was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average number of stools per day up to Week 120 during the end of NTT period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":"3.182"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Positive Specific Antibodies at EOS During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period","description":"Number of participants achieved at least 20% reduction in PS volume at 12 weeks interval up to Week 156 in retrospective observation period was reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PS Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period","description":"Change from baseline in PS volume at 12 weeks interval up to Week 156 in retrospective observation period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.45","spread":"17.770"},{"groupId":"OG001","value":"-12.84","spread":"17.694"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.27","spread":"21.642"},{"groupId":"OG001","value":"-13.49","spread":"14.530"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.65","spread":"20.877"},{"groupId":"OG001","value":"-17.91","spread":"17.069"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.24","spread":"29.646"},{"groupId":"OG001","value":"-26.12","spread":"8.044"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.85","spread":"30.219"},{"groupId":"OG001","value":"-21.35","spread":"12.285"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.65","spread":"30.577"},{"groupId":"OG001","value":"-11.41","spread":"22.030"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.74","spread":"36.078"},{"groupId":"OG001","value":"-15.65","spread":"19.603"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.87","spread":"37.996"},{"groupId":"OG001","value":"-27.34","spread":"16.531"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.35","spread":"29.370"},{"groupId":"OG001","value":"-31.83","spread":"14.872"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.21","spread":"27.480"},{"groupId":"OG001","value":"-30.48","spread":"19.043"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.20","spread":"26.171"},{"groupId":"OG001","value":"-37.70","spread":"12.296"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.79","spread":"29.620"},{"groupId":"OG001","value":"-34.32","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.46","spread":"1.931"},{"groupId":"OG001","value":"-34.43","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in PS Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period","description":"Percent change from baseline in PS volume at 12 weeks interval up to Week 156 of retrospective observation period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.50","spread":"27.853"},{"groupId":"OG001","value":"-24.88","spread":"35.649"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.72","spread":"33.081"},{"groupId":"OG001","value":"-32.10","spread":"31.645"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.21","spread":"34.172"},{"groupId":"OG001","value":"-43.09","spread":"42.753"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.04","spread":"39.390"},{"groupId":"OG001","value":"-65.18","spread":"31.650"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.15","spread":"39.491"},{"groupId":"OG001","value":"-53.61","spread":"37.141"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.19","spread":"40.558"},{"groupId":"OG001","value":"-14.11","spread":"58.452"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.67","spread":"47.108"},{"groupId":"OG001","value":"-30.25","spread":"39.598"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.04","spread":"51.631"},{"groupId":"OG001","value":"-61.19","spread":"29.335"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.62","spread":"48.820"},{"groupId":"OG001","value":"-73.43","spread":"29.298"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.89","spread":"49.366"},{"groupId":"OG001","value":"-69.61","spread":"39.194"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.24","spread":"47.431"},{"groupId":"OG001","value":"-85.92","spread":"17.457"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.70","spread":"44.170"},{"groupId":"OG001","value":"-65.20","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.21","spread":"3.164"},{"groupId":"OG001","value":"-65.42","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PS Caloric Intake at 12 Weeks Interval up to Week 156 of Retrospective Observation Period","description":"Change from baseline in PS caloric intake at 12 weeks interval up to Week 156 of retrospective observation period was reported. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.15","spread":"13.026"},{"groupId":"OG001","value":"-2.64","spread":"18.739"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.96","spread":"16.970"},{"groupId":"OG001","value":"-7.25","spread":"11.916"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.38","spread":"17.148"},{"groupId":"OG001","value":"-6.42","spread":"24.547"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.84","spread":"22.144"},{"groupId":"OG001","value":"-18.11","spread":"7.896"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.55","spread":"23.136"},{"groupId":"OG001","value":"-10.53","spread":"18.538"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.64","spread":"23.642"},{"groupId":"OG001","value":"-0.05","spread":"23.552"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.70","spread":"24.860"},{"groupId":"OG001","value":"-5.24","spread":"23.064"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.08","spread":"23.998"},{"groupId":"OG001","value":"-15.09","spread":"18.604"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.20","spread":"22.875"},{"groupId":"OG001","value":"-19.05","spread":"18.229"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.98","spread":"21.425"},{"groupId":"OG001","value":"-17.18","spread":"23.169"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.93","spread":"18.744"},{"groupId":"OG001","value":"-27.59","spread":"5.114"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.97","spread":"17.977"},{"groupId":"OG001","value":"-25.53","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.55","spread":"4.708"},{"groupId":"OG001","value":"-25.67","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in PS Caloric Intake at 12 Weeks Interval up to Week 156 of Retrospective Observation Period","description":"Percent change from baseline in PS caloric intake at 12 weeks interval up to Week 156 of retrospective observation period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.91","spread":"29.001"},{"groupId":"OG001","value":"7.64","spread":"82.061"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.12","spread":"42.431"},{"groupId":"OG001","value":"-21.29","spread":"37.759"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.29","spread":"41.070"},{"groupId":"OG001","value":"-3.38","spread":"118.167"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.03","spread":"43.924"},{"groupId":"OG001","value":"-59.31","spread":"38.042"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.63","spread":"44.903"},{"groupId":"OG001","value":"-25.65","spread":"83.470"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.48","spread":"45.035"},{"groupId":"OG001","value":"23.26","spread":"99.380"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.42","spread":"45.287"},{"groupId":"OG001","value":"4.41","spread":"102.162"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.12","spread":"46.005"},{"groupId":"OG001","value":"-36.49","spread":"72.357"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.41","spread":"46.034"},{"groupId":"OG001","value":"-50.24","spread":"70.513"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.79","spread":"45.774"},{"groupId":"OG001","value":"-38.58","spread":"97.750"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.37","spread":"40.170"},{"groupId":"OG001","value":"-82.01","spread":"21.165"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.25","spread":"33.618"},{"groupId":"OG001","value":"-60.36","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.66","spread":"7.700"},{"groupId":"OG001","value":"-60.69","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Number of Hours Per Day of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period","description":"Data for this outcome measure was not analyzed and collected because changes from baseline for prescribed hours per day were not collected at baseline in the core study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Percent Change From Baseline in Number of Hours Per Day of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period","description":"Data for this outcome measure was not analyzed and collected because changes from baseline for prescribed hours per day were not collected at baseline in the core study. Hence, percent change was not assessed in this study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Number of Days Per Week of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period","description":"Change from baseline in number of days per Week of PS usage at 12 weeks interval up to Week 156 in retrospective observation period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":"1.469"},{"groupId":"OG001","value":"-1.20","spread":"2.683"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"1.429"},{"groupId":"OG001","value":"-1.00","spread":"2.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"1.562"},{"groupId":"OG001","value":"-2.60","spread":"2.793"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"2.017"},{"groupId":"OG001","value":"-4.50","spread":"2.082"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"2.017"},{"groupId":"OG001","value":"-3.00","spread":"3.536"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"2.060"},{"groupId":"OG001","value":"-1.40","spread":"2.966"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"2.060"},{"groupId":"OG001","value":"-1.40","spread":"2.966"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.17","spread":"2.665"},{"groupId":"OG001","value":"-2.00","spread":"3.536"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"2.365"},{"groupId":"OG001","value":"-3.80","spread":"3.701"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"2.459"},{"groupId":"OG001","value":"-3.80","spread":"3.701"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"2.542"},{"groupId":"OG001","value":"-5.25","spread":"2.062"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"-3.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"-3.00","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Number of Days Per Week of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period","description":"Percent change from baseline in number of days per Week of PS usage at 12 weeks interval up to Week 156 in retrospective observation period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.25","spread":"22.421"},{"groupId":"OG001","value":"-14.86","spread":"41.913"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.17","spread":"20.412"},{"groupId":"OG001","value":"-14.29","spread":"28.571"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.21","spread":"22.309"},{"groupId":"OG001","value":"-34.86","spread":"44.648"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.70","spread":"28.810"},{"groupId":"OG001","value":"-64.29","spread":"29.738"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.70","spread":"28.810"},{"groupId":"OG001","value":"-40.57","spread":"54.638"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.09","spread":"29.424"},{"groupId":"OG001","value":"-17.71","spread":"45.821"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.09","spread":"29.424"},{"groupId":"OG001","value":"-17.71","spread":"45.821"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"38.069"},{"groupId":"OG001","value":"-26.29","spread":"53.886"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.50","spread":"33.783"},{"groupId":"OG001","value":"-52.00","spread":"57.407"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.64","spread":"35.125"},{"groupId":"OG001","value":"-52.00","spread":"57.407"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.29","spread":"36.314"},{"groupId":"OG001","value":"-75.00","spread":"29.451"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"-42.86","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"-42.86","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved At Least 20, 50 and 75% Reduction in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Number of participants who achieved at least 20, 50 and 75% reduction in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Change from baseline in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.18","spread":"19.915"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.59","spread":"29.856"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.05","spread":"29.711"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.10","spread":"30.359"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.49","spread":"24.259"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.57","spread":"26.243"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Percent change from baseline in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.02","spread":"28.611"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.58","spread":"48.150"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.16","spread":"41.805"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.92","spread":"38.466"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-73.49","spread":"34.593"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-78.75","spread":"33.949"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PS Caloric Intake at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Change from baseline in PS caloric intake at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.66","spread":"17.649"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.95","spread":"23.402"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.66","spread":"19.668"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.05","spread":"22.746"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.98","spread":"27.465"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.53","spread":"32.486"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in PS Caloric Intake at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Percent change from baseline in PS caloric intake at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.50","spread":"40.439"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.06","spread":"44.077"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.47","spread":"37.677"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.51","spread":"54.041"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.08","spread":"64.002"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.00","spread":"57.267"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved 100% Reduction in Complete Weaning of PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Number of participants who achieved at least 100% reduction in complete weaning of PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Number of Hours Per Day of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Change from baseline in number of hours per day of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.40","spread":"3.752"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.80","spread":"5.360"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.69","spread":"4.247"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.48","spread":"4.881"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.71","spread":"6.175"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.08","spread":"6.075"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Number of Hours Per Day of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Percent change from baseline in number of hours per day of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.32","spread":"29.732"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.47","spread":"40.476"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.61","spread":"36.973"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.87","spread":"42.693"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-58.85","spread":"52.717"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-66.39","spread":"46.042"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Number of Days Per Week of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Change from baseline in number of days per week of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"1.892"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.93","spread":"2.840"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.03","spread":"3.257"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.99","spread":"3.610"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.83","spread":"3.969"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.37","spread":"3.618"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Number of Days Per Week of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period","description":"Percent change from baseline in number of days per week of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.01","spread":"27.472"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.24","spread":"40.525"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.51","spread":"47.929"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.38","spread":"51.929"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.29","spread":"57.404"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.86","spread":"51.110"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period","description":"PedsQL GCS was used for quality of life assessment. It encompasses 4 dimensions of functioning (physical, emotional, social, school). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"24.326"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"10.726"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"15.717"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":"16.296"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"16.167"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.74","spread":"25.963"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.74","spread":"22.378"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.79","spread":"19.998"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.50","spread":"19.961"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.34","spread":"14.292"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.25","spread":"22.244"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.13","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"18.843"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.67","spread":"24.511"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":"28.591"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":"21.454"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.05","spread":"29.661"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"36.120"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":"33.481"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.71","spread":"35.786"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.00","spread":"40.566"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.50","spread":"37.804"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.63","spread":"56.065"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.50","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.00","spread":"NA"}]}]},{"categories":[]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.67","spread":"19.445"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"20.160"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.00","spread":"24.027"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.75","spread":"16.394"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.64","spread":"23.355"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":"22.500"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"15.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.57","spread":"8.018"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.00","spread":"11.180"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.75","spread":"8.539"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.75","spread":"4.787"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":"NA"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score at End of Last NTT Period During the NTT Periods in Prospective Study Period","description":"PedsQL GCS was used for quality of life assessment. It encompasses 4 dimensions of functioning (physical, emotional, social, school). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.","paramType":null,"dispersionType":null,"classes":[{"categories":[]},{"categories":[]},{"categories":[]},{"categories":[]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Total Score at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period","description":"PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items). Total score was calculated as the sum of all the items over the number of items answered on all the scales. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":"15.742"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.56","spread":"13.372"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"13.622"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.90","spread":"11.664"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.72","spread":"15.051"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.90","spread":"16.018"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":"20.762"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.66","spread":"23.546"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"14.105"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"16.099"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.13","spread":"18.084"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.86","spread":"NA"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Total Score at End of Last NTT Period During the NTT Periods in Prospective Study Period","description":"PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items). Total score was calculated as the sum of all the items over the number of items answered on all the scales. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Module at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period","description":"PedsQL GI symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea. Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study. Subscale score was calculated as the sum of the items over the number of items answered in the scale. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.08","spread":"30.460"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.06","spread":"27.524"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"29.723"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.31","spread":"26.292"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"35.784"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"29.511"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.63","spread":"33.750"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"35.895"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"21.343"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.36","spread":"44.986"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"30.142"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.83","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.79","spread":"23.137"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.33","spread":"23.279"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.48","spread":"15.144"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.72","spread":"19.880"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.27","spread":"22.124"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.19","spread":"21.569"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.13","spread":"18.653"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.95","spread":"26.448"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.71","spread":"23.237"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"30.612"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.95","spread":"22.961"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.14","spread":"NA"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Module at End of Last NTT Period During the NTT Periods in Prospective Study Period","description":"PedsQL GI symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea. Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study. Subscale score was calculated as the sum of the items over the number of items answered in the scale. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.","paramType":null,"dispersionType":null,"classes":[{"categories":[]},{"categories":[]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":24},"commonTop":["Vomiting","Abdominal pain","Upper respiratory tract infection","Headache","Cough"]}}}